<DOC>
	<DOCNO>NCT01735370</DOCNO>
	<brief_summary>This open Label , balance , randomize , single dose , two-treatment , two-sequence , two-period , crossover pivotal study . The purpose study assess bioequivalence Test Product correspond Reference Product fast condition healthy , adult human subject .</brief_summary>
	<brief_title>Bioequivalence Study Etodolac Tablet USP 500 mg Under Fasting Condition</brief_title>
	<detailed_description>Objective pivotal study assess bioequivalence Test Product : Etodolac Tablets USP 500 mg Ipca Laboratories Limited , India correspond Reference Product : Etodolac Tablets USP 500mg Taro Pharmaceutical Industries Ltd. , USA , fast condition healthy , adult , human subject randomize crossover study . The study conduct 36 healthy adult subject . In study period , single 500 mg dose either test reference administer subject per randomization schedule study period 240 mL water ambient temperature sit position . The duration clinical phase approximately 12 day include washout period 9 day administration study drug study period .</detailed_description>
	<mesh_term>Etodolac</mesh_term>
	<criteria>1 . Healthy male nonpregnant female subject within age range 18 45 year ( inclusive ) , time dose . 2 . Subjects ' weight within normal range accord normal value Body Mass Index ( 18.5 24.9 kg/m2 ) minimum 50 kg weight . 3 . Subjects normal health determine personal medical medication history , clinical examination laboratory examination within clinically acceptable reference range . 4 . Subjects normal 12lead electrocardiogram ( ECG ) . 5 . Subjects normal chest XRay ( P/A view ) whose XRay take within 6 month prior dose Period 01 . 6 . Subjects negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . 7 . Subjects negative alcohol breath test . 8 . Subjects willing adhere protocol requirement provide write informed consent . 9 . Subjects negative BetahCG Pregnancy test ( female subject ) . 10 . For Female Subjects : Female child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence , Postmenopausal least 1 year , less 1 year , follow acceptable contraceptive measure mention Surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) . 1 . Hypersensitivity Etodolac related class drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . 3 . History presence significant alcoholism drug abuse . 4 . History presence significant smoking ( 10 cigarette beedi's/day ) . 5 . History presence significant asthma , urticaria allergic reaction . 6 . History presence significant gastric and/or duodenal ulceration . 7 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumour . 8 . History presence cancer . 9 . Difficulty donate blood . 10 . Difficulty swallow solid like tablet capsule . 11 . Use prescribed medication OTC medical product last two week prior dose period 01 . 12 . Major illness 3 month screen . 13 . Participation drug research study within past 3 month . 14 . Donation blood past 3 month screen . 15 . Consumption grapefruit juice , xanthinecontaining product , tobacco containing product alcohol within 48 hour prior dose . 16 . Positive screen test one : HIV , Hepatitis B Hepatitis C. 17 . History presence significant easy bruise bleeding . 18 . History presence significant recent trauma . 19 . Subjects abnormal diet ( whatever reason ) four week precede study . 20 . Female subject currently breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>